Nature's Sunshine Products (NATR) AI Stock Analysis

• Market Cap: $289.58M
• Dividend Yield: N/A
• Average Volume (3M): 113.36K
• Price to Earnings (P/E): 21.8
• Beta (1Y): 0.57
• Revenue Growth: 4.33%
• EPS Growth: -6.33%
• Country: US
• Employees: 819
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): 0.35
• Shares Outstanding: 17,635,551
• 10 Day Avg. Volume: 124,526
• 30 Day Avg. Volume: 113,358
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.76
• Enterprise Value/Revenue: 0.48
• Enterprise Value/Gross Profit: 0.67
• Enterprise Value/Ebitda: 6.13
• 1Y Price Target: $20.67
• Price Target Upside: 27.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 80 Outperform
• Price Target: $19.00 ▲(17.00% Upside)

Nature's Sunshine Products receives a strong overall score of 80, driven by solid financial performance and a positive earnings call that highlighted revenue growth and digital transformation success. Technical analysis supports a bullish outlook, although valuation suggests moderate pricing. Challenges in certain regions and increased expenses are noted but do not significantly detract from the overall positive trajectory.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Digital Transformation

Successful digital transformation enhances customer engagement and operational efficiency, positioning the company for future growth.

Balance Sheet Health

A strong cash position and no debt provide financial flexibility and reduce risk, supporting strategic investments and stability.

Negative Factors

Leadership Change

Leadership changes can create uncertainty and disrupt strategic continuity, potentially impacting long-term business direction and execution.

Regional Challenges

Economic challenges in key regions can hinder growth and profitability, requiring strategic adjustments to maintain market presence.

Increased Expenses

Rising expenses can pressure margins and reduce profitability, necessitating cost management to sustain financial health.

Nature's Sunshine Products Business Overview & Revenue Model

Company Description

Nature's Sunshine Products, Inc., a natural health and wellness company, primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. The company was founded in 1972 and is headquartered in Lehi, Utah.

How the Company Makes Money

Nature's Sunshine Products generates revenue primarily through the sale of its health and wellness products, which are marketed through a direct selling model. This model allows independent distributors to sell products directly to consumers, creating a network of sales representatives who earn commissions based on their sales volume. Key revenue streams include sales of dietary supplements, herbal products, and essential oils. The company also engages in strategic partnerships and collaborations to enhance its product offerings and expand its market reach. Additionally, Nature's Sunshine benefits from a loyal customer base and a growing trend towards natural and wellness-related products, which supports its earnings and overall financial performance.

Nature's Sunshine Products Financial Statement Overview

Summary

Nature's Sunshine Products demonstrates solid financial health with steady revenue growth, strong margins, and a robust balance sheet. While profitability ratios indicate room for improvement, the company's low leverage and strong cash flow position it well for future growth. Maintaining this trajectory could enhance profitability and shareholder value.

Income Statement

The income statement reveals steady revenue growth with a TTM revenue of $460.8 million, marking a 1.42% increase from the previous year. Gross profit margin is robust at 71.78%, indicating effective cost management. However, the net profit margin stands at 3.06%, suggesting limited profitability after expenses. The EBIT margin is 4.40% and EBITDA margin is 6.34%, reflecting moderate operational efficiency. Overall, the company shows a stable growth trajectory with room for improvement in profitability.

Balance Sheet

The balance sheet is strong with a low debt-to-equity ratio of 0.10, demonstrating conservative leverage. Return on Equity (ROE) is 8.62%, indicating decent returns for shareholders. Equity ratio stands at 64.22%, highlighting a solid equity position and financial stability. Overall, the company maintains a healthy balance sheet with low risk and good equity utilization.

Cash Flow

Cash flow analysis shows positive free cash flow growth at 11.52% compared to the prior year, enhancing financial flexibility. The operating cash flow to net income ratio is 1.54, suggesting efficient cash generation relative to its earnings. The free cash flow to net income ratio is robust at 1.13, indicating strong cash conversion. Despite this, the company should focus on sustaining cash flow improvements to support future growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	460.82M	454.36M	445.32M	421.91M	444.08M	385.20M
Gross Profit	330.72M	324.69M	321.13M	299.76M	328.62M	283.93M
EBITDA	35.99M	32.79M	32.09M	31.15M	45.83M	32.23M
Net Income	14.11M	7.70M	15.08M	-390.00K	28.85M	21.34M
Balance Sheet
Total Assets	254.88M	240.85M	249.77M	229.78M	258.87M	249.50M
Cash, Cash Equivalents and Short-Term Investments	81.34M	84.70M	82.37M	60.03M	86.18M	92.07M
Total Debt	15.63M	14.20M	14.92M	19.18M	22.99M	26.33M
Total Liabilities	91.19M	79.86M	90.23M	82.73M	97.47M	92.26M
Stockholders Equity	157.68M	155.31M	154.06M	142.91M	158.20M	155.39M
Cash Flow
Free Cash Flow	15.98M	14.33M	30.75M	-6.92M	27.94M	32.75M
Operating Cash Flow	21.74M	25.30M	41.23M	710.00K	34.61M	37.66M
Investing Cash Flow	-5.76M	-10.97M	-10.48M	-7.63M	-6.61M	-4.91M
Financing Cash Flow	-14.16M	-9.90M	-7.96M	-16.25M	-31.72M	3.88M

Nature's Sunshine Products Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 16.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NATR, the sentiment is Neutral. The current price of 16.24 is below the 20-day moving average (MA) of 16.80, above the 50-day MA of 16.11, and above the 200-day MA of 14.60, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 45.48 is Neutral, neither overbought nor oversold. The STOCH value of 27.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NATR.

Nature's Sunshine Products Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	80 Outperform	$289.58M	21.78	9.15%	―	4.33%	-6.33%
FTLF	75 Outperform	178.90M	23.94	24.87%	―	3.91%	-1.39%
MAMA	75 Outperform	437.79M	94.49	15.29%	―	19.34%	-12.64%
LFVN	67 Neutral	130.46M	13.62	28.30%	1.70%	14.17%	235.39%
LSF	49 Neutral	66.55M	-55.65	-13.79%	―	22.79%	74.00%
HAIN	47 Neutral	148.98M	-0.26	-111.75%	―	-10.17%	-609.02%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

Nature's Sunshine Products Corporate Events

Nature’s Sunshine Buys Out Fosun Pharma’s Joint Ventures

On June 27, 2025, Fosun Pharma sold a significant portion of its shares in Nature’s Sunshine Products, reducing its ownership below 5%. Consequently, on June 30, 2025, Nature’s Sunshine Products agreed to repurchase Fosun Pharma’s interests in their joint ventures in Hong Kong and Shanghai for a total of $7 million, subject to regulatory approvals in China.

Nature’s Sunshine Announces Secondary Offering and Buyback

On June 25, 2025, Nature’s Sunshine Products, Inc. entered into an underwriting agreement for a secondary public offering of 2,854,607 shares of common stock at $12.00 per share, with no proceeds going to the company. A concurrent share repurchase agreement was also approved, allowing the company to buy back up to $15 million of its shares, potentially impacting its stock value and market positioning.

Nature’s Sunshine CEO Terrence Moorehead Steps Down

On May 28, 2025, Terrence O. Moorehead, the President and CEO of Nature’s Sunshine Products, Inc., announced his decision to step down from his roles, pending the appointment of a successor. This leadership change, announced on June 2, 2025, could impact the company’s strategic direction and stakeholder confidence as it navigates the transition.